Additional file 7 of Comprehensive analysis of alternative splicing across multiple transcriptomic cohorts reveals prognostic signatures in prostate cancer

Additional file 7: Table S7. Screening for candidate prognostic events associated with BCRFS. (a) Univariate Cox regression analysis of overlapping differentially expressed alternative splicing (DEAS) events identified in both The Cancer Genome Atlas-Prostate Adenocarcinoma (TCGA-PRAD) and PRJEB2449 cohorts, as related to the biochemical recurrence-free survival (BCRFS) of prostate cancer (PCa) patients.z: the values of the Wald statistic; HR: hazard ratio of the event; HR.95L: the lower limit of 95% confidence interval; HR.95H: the upper limit of the 95% confidence interval; p: p-values obtained from the likelihood ratio test. (b) Kaplan–Meier analysis of the overlapping differentially expressed alternative splicing (DEAS) events identified in both The Cancer Genome Atlas-Prostate Adenocarcinoma (TCGA-PRAD) and PRJEB2449 cohorts, with regard to the biochemical recurrence-free survival (BCRFS) of prostate cancer (PCa) patients. 'p-value' refers to the statistical significance as determined by the log-rank test. (c) Multivariate Cox regression analysis of the 21 intersected events identified from both the univariate Cox regression and the Kaplan–Meier (KM) analyses, pertaining to the biochemical recurrence-free survival (BCRFS) of prostate cancer (PCa) patients. The coefficients are represented by 'coef'; HR: hazard ratio of the event; HR.95L: the lower limit of 95% confidence interval; HR.95H: the upper limit of the 95% confidence interval; p: p-values obtained from the likelihood ratio test.